This article was originally published in The Gray Sheet
Biocompatible coating technology transfer to Boston Scientific will continue for use with stents, grafts, vena cava filters and other implantable medical devices. The decision builds on a 1996 agreement between the firms, which included an equity investment by Boston Scientific. InnerDyne has made public three similar contracts related to the technology in the device area. Third-party deals related to the coating and thermal ablation technology contribute to a 39% increase in revenues in the second quarter ended June 30 to $4.4 mil., InnerDyne reports, as the firm almost breaks even
You may also be interested in...
Previous businesses FDA warned about COVID-19 claims for chlorine dioxide, a bleach solution, were marketing dietary supplements unlawfully. But Pro Breath MD's oral rinses available under the Dentist Select and OraCare brands are allowed and FDA isn’t asking the firm to discontinue distribution.
The Stark Law ban on self-referrals wouldn’t apply to some physician owners of advanced imaging facilities under a CMS final rule.
Pfizer’s abrocitinib and Biogen/Eisai’s aducanumab are among a host of new investigational products that are under review by the European Medicines Agency.